Dr. Soltesz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9500 Euclid Ave
Cleveland, OH 44195Phone+1 800-223-2273
Education & Training
- Brigham and Women's Hospital/Children's HospitalFellowship, Thoracic Surgery, 2005 - 2007
- Brigham and Women's HospitalResidency, Surgery, 1998 - 2005
- Harvard Medical SchoolClass of 1998
Certifications & Licensure
- OH State Medical License 2006 - 2026
- PA State Medical License 2009 - 2016
- MA State Medical License 2001 - 2010
- American Board of Thoracic Surgery Thoracic and Cardiac Surgery
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Randomized Study of Organ Care System Cardiac for Preservation of Donated Hearts for Eventual Transplantation Start of enrollment: 2009 Mar 01
- The ARIES HeartMate 3 Pump IDE Study Start of enrollment: 2020 Jul 14
Roles: Contact, Principal Investigator, Sub-Investigator
Publications & Presentations
PubMed
- Time-varying analyses of survival and outcomes in patients with HeartMate 3 left ventricular assist devices.Aaron J Weiss, Jean-Luc A Maigrot, Michael Z Y Tong, Lucy Thuita, Nicholas G Smedira
European Journal of Heart Failure. 2025-01-09 - Trajectories following Impella 5.5 support are associated with initial presentation acuity.Jean-Luc A Maigrot, Randall C Starling, Edward G Soltesz, Nicholas G Smedira, Michael Z Y Tong
Artificial Organs. 2025-01-01 - Reoperative Interval and Perioperative Mortality Risk in Cardiac Surgery.Richard Ramsingh, Mariana Kawalet, Joshua E Insler, Jules J Bakhos, Abhishek Sharma
JAMA Surgery. 2024-12-18
Press Mentions
- Clinical Assessment and Collaboration Drive Sustained Improvement in Post-CABG Prolonged Ventilation RatesNovember 29th, 2024
- Auf Der STS-Jahrestagung Vorgestellte Umfangreiche Klinische Studie Zeigt Überlebensrate Von 79 % Bei Behandlung Mit Impella 5.5 Mit SmartAssist HerzpumpeFebruary 1st, 2021
- Large Clinical Study Presented at STS 2021 Finds 79% Survival Rate with Impella 5.5 with SmartAssistJanuary 29th, 2021
- Join now to see all
Grant Support
- Gene Therapy For Chronic Heart FailureNational Heart, Lung, And Blood Institute2003
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: